Currax acquires biopharma firm focused on weight loss treatments

Currax Pharmaceuticals, a biopharmaceutical company based in Morristown, announced Friday it has acquired Nalpropion Pharmaceuticals, a biopharmaceutical company focused on the treatment of weight loss.

Under terms of the deal, Currax will now own the rights to Contrave, a prescription weight loss medication in the United States.

“It is exciting to announce our second acquisition in as many days,” George Hampton, CEO of Currax Pharmaceuticals, said.  “This acquisition bolsters our branded portfolio and demonstrates that we are successfully executing on our business strategy to acquire clinically differentiated medicines with high potential for growth and extended IP life.”

Financial and other terms were not disclosed.